<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="case-report">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Diagn Pathol</journal-id>
      <journal-id journal-id-type="iso-abbrev">Diagn Pathol</journal-id>
      <journal-title-group>
        <journal-title>Diagnostic Pathology</journal-title>
      </journal-title-group>
      <issn pub-type="epub">1746-1596</issn>
      <publisher>
        <publisher-name>BioMed Central</publisher-name>
        <publisher-loc>London</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">27612448</article-id>
      <article-id pub-id-type="pmc">5017047</article-id>
      <article-id pub-id-type="publisher-id">539</article-id>
      <article-id pub-id-type="doi">10.1186/s13000-016-0539-6</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Case Report</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Primary rare anaplastic large cell lymphoma, ALK positive in small intestine: case report and review of the literature</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author" equal-contrib="yes">
          <name>
            <surname>Cao</surname>
            <given-names>Qinghua</given-names>
          </name>
          <address>
            <email>bpigeon@163.com</email>
          </address>
          <xref ref-type="aff" rid="Aff1">1</xref>
        </contrib>
        <contrib contrib-type="author" equal-contrib="yes">
          <name>
            <surname>Liu</surname>
            <given-names>Fang</given-names>
          </name>
          <address>
            <email>liufang7250@163.com</email>
          </address>
          <xref ref-type="aff" rid="Aff2">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Li</surname>
            <given-names>Shurong</given-names>
          </name>
          <address>
            <email>sysusums00@sina.com</email>
          </address>
          <xref ref-type="aff" rid="Aff3">3</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Liu</surname>
            <given-names>Ni</given-names>
          </name>
          <address>
            <email>349762514@qq.com</email>
          </address>
          <xref ref-type="aff" rid="Aff1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Li</surname>
            <given-names>Lihui</given-names>
          </name>
          <address>
            <email>664573134@qq.com</email>
          </address>
          <xref ref-type="aff" rid="Aff1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Li</surname>
            <given-names>Changzhao</given-names>
          </name>
          <address>
            <email>changzhaoli@gmail.com</email>
          </address>
          <xref ref-type="aff" rid="Aff1">1</xref>
        </contrib>
        <contrib contrib-type="author" corresp="yes">
          <name>
            <surname>Peng</surname>
            <given-names>Tingsheng</given-names>
          </name>
          <address>
            <email>pengtsh@mail.sysu.edu.cn</email>
          </address>
          <xref ref-type="aff" rid="Aff1">1</xref>
        </contrib>
        <aff id="Aff1"><label>1</label>Department of Pathology, The First Affiliated Hospital of Sun Yat-sen University, #58, Zhongshan Road II, Guangzhou, 510080 China </aff>
        <aff id="Aff2"><label>2</label>Department of Oncology, Nanfang Hospital, Southern Medical University, #1838 Guangzhou Dadao Bei Avenue, Guangzhou, 510515 China </aff>
        <aff id="Aff3"><label>3</label>Department of Radiology, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, 510080 China </aff>
      </contrib-group>
      <pub-date pub-type="epub">
        <day>9</day>
        <month>9</month>
        <year>2016</year>
      </pub-date>
      <pub-date pub-type="pmc-release">
        <day>9</day>
        <month>9</month>
        <year>2016</year>
      </pub-date>
      <pub-date pub-type="collection">
        <year>2016</year>
      </pub-date>
      <volume>11</volume>
      <issue>1</issue>
      <elocation-id>83</elocation-id>
      <history>
        <date date-type="received">
          <day>24</day>
          <month>4</month>
          <year>2016</year>
        </date>
        <date date-type="accepted">
          <day>2</day>
          <month>9</month>
          <year>2016</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>&#xA9; The Author(s). 2016</copyright-statement>
        <license license-type="OpenAccess">
          <license-p>
<bold>Open Access</bold>This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p>
        </license>
      </permissions>
      <abstract id="Abs1">
        <sec>
          <title>Background</title>
          <p>Primary anaplastic large cell lymphoma, ALK positive in small intestine is clinically rare&#xA0;&#xFEFF;and the clinical, radiological and pathological information are generally not &#xFEFF;availab&#xFEFF;le&#xFEFF;. Here, we report a case of 32-year-old male with ALK positive anaplastic large cell lymphoma at the junction of jejunum and ileum, and highlight the clinicopathological features and the differential diagnosis of this type lymphoma.</p>
        </sec>
        <sec>
          <title>Case presentation</title>
          <p>The patient presented with right middle abdominal mass for 1&#xA0;month with sporadic pain. Computed tomography (CT) showed a mass measured 8.5&#x2009;&#xD7;&#x2009;7.4&#x2009;&#xD7;&#x2009;4&#xA0;cm at the junction of jejunum and ileum. The diagnosis was made after pathological examination of the excised tissue by enterectomy. Grossly, the mass was located predominately in intestinal wall with grayish appearance and blurry boundary. Microscopically, almost all layers of the intestinal wall were infiltrated by pleomorphic tumor cells with diffuse and cohesive growth pattern. The neoplastic cells were mainly medium to large size with moderate basophilic cytoplasm. Most of them had hyperchromatic nuclei and prominent nucleoli. &#x201C;Hallmark&#x201D; cells were easily detected. Immunohistochemically, tumor cells are characterized by CD30, ALK, CD5, TIA-1, Granzyme B, EMA positive staining, and CD2, CD3, CD7, CD4, CD8, CD20, CD79a negative staining. The Epstein-Barr virus encoded RNAs (EBERs) genome was also negative. A diagnosis as primary small intestinal ALK positive anaplastic large cell lymphoma was finally made. The patient received CHOP chemotherapy and is alive till now without recurrence 5&#xA0;months after enterectomy.</p>
        </sec>
        <sec>
          <title>Conclusions</title>
          <p>Primary small intestinal ALK positive anaplastic large cell lymphoma is rare. The accurate diagnosis should be based on combined consideration of clinical characteristics, CT image and pathological features, and should be distinguished from other lymphomas or solid tumors in small intestine.</p>
        </sec>
      </abstract>
      <kwd-group xml:lang="en">
        <title>Keywords</title>
        <kwd>Anaplastic large cell lymphoma</kwd>
        <kwd>ALK positive</kwd>
        <kwd>Small intestine</kwd>
      </kwd-group>
      <custom-meta-group>
        <custom-meta>
          <meta-name>issue-copyright-statement</meta-name>
          <meta-value>&#xA9; The Author(s) 2016</meta-value>
        </custom-meta>
      </custom-meta-group>
    </article-meta>
  </front>
  <body>
    <sec id="Sec1">
      <title>Background</title>
      <p>Anaplastic large cell lymphoma (ALCL) was first identified by Stein et al. in 1985 [<xref ref-type="bibr" rid="CR1">1</xref>]. It belongs to peripheral T-cell lymphoma characterized by large neoplastic cells with abundant cytoplasm and eccentric horseshoe- or kidney-shaped nuclei. According to the WHO classification (4<sup>th</sup> Edition), primary systemic ALCL includes two distinct entities: anaplastic lymphoma kinase (ALK) positive and ALK negative [<xref ref-type="bibr" rid="CR2">2</xref>]. ALCL mostly affects lymph nodes, with uncommon involvement of extra-nodal sites including soft tissue, bone, lung and liver [<xref ref-type="bibr" rid="CR3">3</xref>]. Cases of ALCL involving small intestine are therefore very rare. So far, there are only a few case reports in the literature [<xref ref-type="bibr" rid="CR4">4</xref>&#x2013;<xref ref-type="bibr" rid="CR7">7</xref>]. Nevertheless, detailed clinical, radiological and/or pathological information of these cases are generally not available. Herein, we report a rare case of primary ALK positive ALCL involving small intestine accompanied with comprehensive clinicopathological features and discussion of differential diagnosis.</p>
    </sec>
    <sec id="Sec2">
      <title>Case presentation</title>
      <sec id="Sec3">
        <title>Clinical history</title>
        <p>A 32-year-old man presented with right middle abdominal mass for 1&#xA0;month and sporadic pain without fever, nausea, vomit or diarrhea. The patient was admitted to our hospital due to sudden severe pain in the abdomen. Physical examinations showed no abnormality and there was absence of palpable superficial lymphadenopathy. A computed tomography (CT) scan showed a mass measured 8.5&#x2009;&#xD7;&#x2009;7.4&#x2009;&#xD7;&#x2009;4&#xA0;cm at the junction of jejunum and ileum involving the adjacent intestinal wall and adipose tissue (Fig.&#xA0;<xref rid="Fig1" ref-type="fig">1</xref>). The colon and rectum were not affected, and there was no obvious involvement of the mesenteric lymph nodes in the immediate vicinity. The liver and spleen were also normal in CT image. There was no obvious enlargement of the mediastinal lymph nodes by CT scanning of thorax. Laboratory examinations revealed negative results for tumor markers of digestive tract including AFP, CEA, CA125, SCC and CA199. Blood routine examination showed white blood cell count at 5.42&#x2009;&#xD7;&#x2009;10<sup>9</sup>/L, the lymphocyte count at 1.5&#x2009;&#xD7;&#x2009;10<sup>9</sup>/L, the red cell count at 5.33&#x2009;&#xD7;&#x2009;10<sup>12</sup>/L, hemoglobin count at 142&#xA0;g/L, and the platelet count at 350&#x2009;&#xD7;&#x2009;10<sup>9</sup>/L respectively. All the parameters of the peripheral blood cells were found in normal range. After the final diagnosis as primary ALK positive anaplastic large cell lymphoma, the patient received CHOP chemotherapy and is alive till now without recurrence 5&#xA0;months after jejunectomy and ileectomy. Material and methods&#x201A; The specimen was fixed in a 10&#xA0;% neutral formalin solution and embedded in paraffin. A 4-&#x3BC;m-thick section was stained with hematoxylin-eosin (H&amp;E) for routine microscopy. Immunohistochemical (IHC) staining was performed using the EnVision Detection System (DAKO, Denmark). Commercially available monoclonal antibodies were employed CD20 (Mouse mAb(L26);1:200), CD79a (Mouse mAb;1:200), CD2 (Mouse mAb(AB75);1:200), CD3&#x3B5; (Mouse mAb (F7.2.38);1:200), CD5 (Mouse mAb(CD5/54/F6);1:300), CD7 (Mouse mAb (CBC. 37);1:200), CD4 (Mouse mAb(4B12);1:200), CD8 (Mouse mAb (C8/ 144B);1:200),CD30 (Mouse mAb(Ber-H2);1:200), ALK (Mouse mAb (ALK1);1:200), Granzyme B (Mouse mAb(GrB-7);1:400), EMA (Mouse mAb(MC-7);1:200), CD10 (Mouse mAb(SS2/36);1:200), Bcl-2 (Mouse mAb(8C8); 1:500), Bcl-6 (Mouse mAb (PG-B6p);1:200), MUM-1(Mouse mAb(Mumlp);1:200), CD38(Mouse mAb (HIT2);1:200), CD138(Mouse mAb(MI15);1:200), CD56(Mouse mAb(123C3);1:300), CyclinD1 (Mouse mAb(DCS-6);1:200), CD21 (Mouse mAb(1&#xA0;F8);1:200), Kappa (Mouse mAb(R10-21-F3);1:400), Lambda (Mouse mAb(N10/2);1:200) and Ki67 (Mouse mAb(MIB-1);1:200). The primary antibodies of TIA-1(Mouse mAb (2G9A10F5);1:200) were from Zhongshan company.<fig id="Fig1"><label>Fig. 1</label><caption><p>Computed tomography (CT) scan of an abdominal mass. CT showed a mass involved small intestines measured 8.5&#x2009;&#xD7;&#x2009;7.4&#x2009;&#xD7;&#x2009;4&#xA0;cm in coronal view (<bold>a</bold>) sagittal view (<bold>b</bold>) and transverse section (<bold>c</bold>)</p></caption><graphic xlink:href="13000_2016_539_Fig1_HTML" id="MO1"/></fig></p>
        <p>In situ hybridization (ISH) with Epstein-Barr virus (EBV)-encoded small RNA (EBER) oligonucleotides was used to test the specimens for the presence of EBV small RNA in formalin-fixed, paraffin-embedded sections using a hybridization kit (DAKO, Denmark).</p>
      </sec>
      <sec id="Sec4">
        <title>Pathological findings</title>
        <p>Grossly, the mass is measured as 9&#x2009;&#xD7;&#x2009;7.5&#x2009;&#xD7;&#x2009;4&#xA0;cm with local invasion of small intestine. On the cut surface, normal structures of intestinal wall were totally destroyed. The mass was located predominately in intestinal wall with grayish appearance and unclear boundary (Fig.&#xA0;<xref rid="Fig2" ref-type="fig">2</xref>). Hemorrhage and necrosis were absent.<fig id="Fig2"><label>Fig. 2</label><caption><p>Macroscopic appearance of the intestinal mass (arrows). Cut surface showed normal structures of intestinal wall were totally destroyed. The mass was located predominately in intestinal wall with grayish appearance and breezing boundary</p></caption><graphic xlink:href="13000_2016_539_Fig2_HTML" id="MO2"/></fig></p>
        <p>Microscopically, almost all layers of the intestinal wall were infiltrated by pleomorphic tumor cells with diffuse and cohesive proliferation pattern (Fig.&#xA0;<xref rid="Fig3" ref-type="fig">3a</xref>). The neoplastic cells were mainly medium to large size with moderate slightly basophilic cytoplasm. Most of them had hyperchromatic nuclei and prominent nucleoli showing immunoblastic and plasmablastic cell features. Hallmark large cells with eccentric horseshoe- or kidney-shaped nuclei often with an eosinophilic region near the nucleus, were detected easily. Additionally, neoplastic cells with mirror-image nuclei resembling Reed-Sternberg cells were also identified (Fig.&#xA0;<xref rid="Fig3" ref-type="fig">3b</xref>, <xref rid="Fig3" ref-type="fig">c</xref>). Mitotic cells were frequently observed.<fig id="Fig3"><label>Fig. 3</label><caption><p>Microscopic features of the intestinal tumor. <bold>a</bold> The intestinal wall were infiltrated by pleomorphic tumor cells with sheet-like pattern (HE&#x2009;&#xD7;&#x2009;40); <bold>b c</bold> The neoplastic cells were mainly medium to large size with moderate pale cytoplasm, hyperchromatic nuclei and prominent nucleoli. &#x201C;Hallmark&#x201D; cells were easily found. Reed-Sternberg cell-like cell can be detected (HE&#x2009;&#xD7;&#x2009;400); <bold>d</bold> Tumor cell showed nuclear and cytoplasmic staining for ALK; Tumor cells were positive for CD30 <bold>e</bold> CD5 <bold>f</bold> TIA-1 <bold>i</bold> negative for CD4 <bold>g</bold> CD8 <bold>h</bold> (Envision&#x2009;&#xD7;&#x2009;100); <bold>j</bold> Ki67 staining showed almost 80&#xA0;% proliferation index (Envision&#x2009;&#xD7;&#x2009;100)</p></caption><graphic xlink:href="13000_2016_539_Fig3_HTML" id="MO3"/></fig></p>
        <p>Immunohistochemically, the neoplastic cells were ALK positive with both nuclear and cytoplasm staining (Fig.&#xA0;<xref rid="Fig3" ref-type="fig">3d</xref>). In addition, these cells are positive for CD30 (Fig.&#xA0;<xref rid="Fig3" ref-type="fig">3e</xref>), CD5 (Fig.&#xA0;<xref rid="Fig3" ref-type="fig">3f</xref>), TIA-1 (Fig.&#xA0;<xref rid="Fig3" ref-type="fig">3i</xref>), Granzyme B and EMA, whereas negative for all of others biomarkers including CK, CD2, CD3, CD7, CD4 (Fig.&#xA0;<xref rid="Fig3" ref-type="fig">3g</xref>), CD8 (Fig.&#xA0;<xref rid="Fig3" ref-type="fig">3h</xref>), CD56, CD10, Bcl-6, Mum-1, Bcl-2, CD38, CD138, Kappa, Lambda, CD21, and CyclinD1. The proliferation index was approximately 80&#xA0;% as assessed by Ki-67 staining (Fig.&#xA0;<xref rid="Fig3" ref-type="fig">3j</xref>). In situ hybridization (ISH) for EBERs study showed no positive signals.</p>
        <p>Based on the above findings, this tumor was diagnosed as anaplastic large cell lymphoma (ALCL), ALK positive. Bone marrow biopsy revealed no tumor cells infiltration.</p>
      </sec>
    </sec>
    <sec id="Sec5">
      <title>Discussion</title>
      <p>Primary gastrointestinal (GI) tract lymphoma is uncommon and only accounts for 1&#x2013;4&#xA0;% of all GI malignances [<xref ref-type="bibr" rid="CR8">8</xref>]. According to Dawson et al. [<xref ref-type="bibr" rid="CR9">9</xref>], the diagnosis of GI lymphoma should meet the following 5 criteria: (1) absence of palpable superficial lymphadenopathy; (2) no evidence of enlarged mediastinal lymph nodes; (3) normal total and differential white blood cell counts; (4) a predominance of bowel lesions at laparotomy with only the lymph nodes obviously affected in the immediate vicinity; (5) absence of tumor involvement of the liver and spleen. Small intestine is the second most common site affected by primary GI lymphoma which ranks after stomach [<xref ref-type="bibr" rid="CR10">10</xref>]. Intestinal B-cell lymphomas occur more frequently than T-cell lymphomas at the ratio of 6:1 [<xref ref-type="bibr" rid="CR11">11</xref>]. As reported, the most common subtype of primary intestinal lymphoma is diffuse large B-cell lymphoma and extra-nodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma) [<xref ref-type="bibr" rid="CR10">10</xref>&#x2013;<xref ref-type="bibr" rid="CR12">12</xref>]. Among the T-cell lymphomas of GI tract, peripheral T-cell lymphomas (PTCL), enteropathy-associated T-cell lymphoma (EATL) and NK/T-cell lymphoma (NK/TL) are the common subtypes [<xref ref-type="bibr" rid="CR12">12</xref>, <xref ref-type="bibr" rid="CR13">13</xref>]. In a retrospective Korean study, 42 primary GI T-cell lymphomas were assessed out of which 17 cases are located in small intestine. Among the 17 small intestinal T-cell lymphomas, 10 lesions (58.8&#xA0;%) could be classified as EATL type II, 4 cases (23.5&#xA0;%) as NK/TL, 2 cases (11.8&#xA0;%) as PTCL, and only 1 case (9.5&#xA0;%) as ALCL [<xref ref-type="bibr" rid="CR5">5</xref>]. Another study from Japan reported only 1 case of ALCL (6.7&#xA0;%) among 15 intestinal T-cell lymphomas in small intestine [<xref ref-type="bibr" rid="CR6">6</xref>]. Hence, ALCL primarily occurred from small intestine is very rare.</p>
      <p>According to WHO classification of tumors of hematopoietic and lymphoid tissues (4th Edition), ALCL was divided into ALK-positive and ALK-negative subtypes based on expression of ALK or ALK gene rearrangement [<xref ref-type="bibr" rid="CR2">2</xref>]. ALK/Nucleophosmin (NPM1) gene fusion was the most common genetic alteration. In addition, variant ALK rearrangement partners have been recognized subsequently including TPM3, ATIC, and TFG. Mechanistically, rearrangements of these genes result in the up-regulation of ALK protein. Moreover, the pattern of ALK immunostaining depends on different types of genetic alterations [<xref ref-type="bibr" rid="CR14">14</xref>, <xref ref-type="bibr" rid="CR15">15</xref>]. In this regard, ALK/NPM1 fusion is characterized by both nucleus and cytoplasm staining, whereas fusions of ALK with other partners lead to diffuse cytoplasmic staining only [<xref ref-type="bibr" rid="CR16">16</xref>]. Compared with ALK-negative ALCL, ALK positive ALCL occurs more frequently in younger patients with favorable outcomes [<xref ref-type="bibr" rid="CR17">17</xref>, <xref ref-type="bibr" rid="CR18">18</xref>]. Most of the patients diagnosed with ALK negative ALCL are reported to have cutaneous, hepatic, or gastrointestinal lesions [<xref ref-type="bibr" rid="CR18">18</xref>]. In this regard, Kim identified 4 ALK negative ALCL in GI tract including 2 in duodenum, 1 in large intestine, and 1 in small intestine [<xref ref-type="bibr" rid="CR5">5</xref>]. In another report by Carey MJ, only 3 ALK negative cases were found out of 4 small intestinal ALCL [<xref ref-type="bibr" rid="CR4">4</xref>]. Based on our observations and other reports, it seems that ALK negative ALCL tends to invade intestine. However, since the number of cases is very small, a larger patient cohort is needed to make a solid conclusion.</p>
      <p>Moreover, diagnosis of intestinal ALCL should be made after exclusion of other lymphomas which show similar cell morphology and/or ALK positive staining. The most important differential diagnosis was ALK positive diffuse large B cell lymphoma (ALK positive DLBCL), which was now considered as a distinct entity [<xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR19">19</xref>]. It was characterized by monomorphic large plasmablast- or immunoblast-like cells with large central nucleoli. It is histologically very close to ALCL and metastatic carcinoma in lymph node at low magnification because of its sinusoidal growth pattern. The neoplastic cells often lack the expression of lineage-associated leukocyte antigens as CD3, CD5, CD20, or CD79a, but express ALK [<xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR19">19</xref>, <xref ref-type="bibr" rid="CR20">20</xref>]. Therefore it could lead to the diagnosis of ALCL &#x201C;null cell&#x201D; phenotype. However, ALK positive DLBCL constantly lack the expression of CD30 in immunohistochemistry, and strongly express plasma cell markers such as CD138 and CD38, which demonstrates the features of terminally differentiated B-lineage origin of the tumor cells. Moreover, unlike both the nucleus and cytoplasm staining in ALCL, the staining of ALK in DLBCL exhibits granular cytoplasmic staining indicating the CLTC/ALK fusion protein [<xref ref-type="bibr" rid="CR19">19</xref>, <xref ref-type="bibr" rid="CR20">20</xref>]. In the present case, besides ALK and CD30 expression, the neoplastic cells were also positive for T lymphocyte lineage markers as CD5, TIA-1, and Granzyme B, while negative for CD20, CD79a, CD38, CD138, suggesting the T-cell origin of these cells and the diagnosis of ALK positive ALCL.</p>
      <p>Plasmablastic Lymphoma (PBL) should also be considered as one of the differential diagnosis because of the morphology of the neoplastic cells mimicking centroblastic and immunoblastic cells. The neoplastic cells of plasmablastic lymphoma expressed markers characterizing plasma cell phenotype including CD 138, CD38, Vs38c either kappa or lambda light chain, and IRF4/MUM1, whereas without the expression of T cell phenotype. Although the neoplastic cells frequently expressed EMA or CD30, they did not express ALK [<xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR21">21</xref>]. Moreover, EBV EBER in situ hybridization is positive in 60&#x2013;75&#xA0;% of the cases of PBL [<xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR21">21</xref>]. Based on the immunophenotype in this case, the diagnosis as PBL was not correct.</p>
      <p>Peripheral T-cell lymphoma, not other specified (PTCL, NOS) deserves additional attention in terms of differential diagnosis. It encompassed all mature T-cell neoplasms lacking specific features that would allow its categorization in any of the better-defined subtypes of post-thymic T-cell lymphoma. In some cases, tumor cells infiltrate lymphatic sinuses and consist of CD30 positive large cells predominantly, which result in difficulty of distinguishing it from ALK negative ALCL. In fact, diagnostic criteria for ALK negative ALCL are still evolving, particularly in distinguishing it from other CD30 positive PTCL, NOS [<xref ref-type="bibr" rid="CR15">15</xref>, <xref ref-type="bibr" rid="CR22">22</xref>]. In ALK negative ALCL, all tumor cells are positive for CD30, mainly on the cell membrane and in the Golgi region. Particularly, the staining of CD30 are strong and of equal intensity in all the tumor cells [<xref ref-type="bibr" rid="CR16">16</xref>, <xref ref-type="bibr" rid="CR23">23</xref>]. By contrast, CD30 staining in PTCL, NOS is usually heterogeneous and comparatively weaker than that in ALK negative ALCL [<xref ref-type="bibr" rid="CR23">23</xref>]. Additionally, the diagnosis of ALK negative ALCL should be reserved for cases with the morphology of ALCL accompanied with a cytotoxic T-cell phenotype including TIA-1, perforin and Granzyme B [<xref ref-type="bibr" rid="CR24">24</xref>]. Nevertheless, other pathologists consider ALK negative ALCL as an anaplastic variant of PTCL, NOS, in light of its poor prognosis and partially overlapping phenotype [<xref ref-type="bibr" rid="CR18">18</xref>, <xref ref-type="bibr" rid="CR25">25</xref>, <xref ref-type="bibr" rid="CR26">26</xref>].</p>
      <p>In addition, ALCL occured in the GI tract must be distinguished from enteropathy associated T-cell lymphoma (EATL), type I, which is considered as a complication of celiac disease (gluten-sensitive). In Type I EATL, the cytological composition of tumor cells is varied, and more polymorphous than Type II lymphomas [<xref ref-type="bibr" rid="CR25">25</xref>, <xref ref-type="bibr" rid="CR27">27</xref>]. In this regard, ALK negative ALCL may closely resemble CD30 positive EATL. However, unlike ALCL, usually EATL is not positive for both EMA and ALK. In addition, EATL is mainly CD8 positive rather than CD4 positive. Its association with celiac disease or villous atrophy further distinguishes itself with ALK positive ALCL [<xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR28">28</xref>].</p>
      <p>Since some of the tumor cells in ALCL resemble classic Reed-Sternberg cells which are &#x201C;hallmark&#x201D; cells in Hodgkin&#x2019;s lymphoma (HL), differential diagnosis should also include HL. Fortunately, it is not difficult to differentiate HL from ALCL if it is ALK positive, but at times it may be a challenge when it comes to ALK negative ALCL. In this case, expression of EMA, clusterin, or CD56 in tumor cells may help to support a diagnosis of ALK negative ALCL, as the staining of these markers are known to be absent in HL [<xref ref-type="bibr" rid="CR29">29</xref>]. Jaffe have suggested that HL-like ALK negative ALCL should be diagnosed only when tumor cell morphology closely resemble Hodgkin&#x2019;s lymphoma but immunohistochemical study show characteristics of ALCL (positive staining for CD30, EMA, CD3 but negative for EBV and B-cell markers) [<xref ref-type="bibr" rid="CR24">24</xref>].</p>
      <p>In addition to lymphatic tissue tumor, ALK rearrangements can also be detected in other malignancies, including inflammatory myofibroblastic tumors [<xref ref-type="bibr" rid="CR30">30</xref>, <xref ref-type="bibr" rid="CR31">31</xref>], non-small cell lung cancers [<xref ref-type="bibr" rid="CR32">32</xref>], neuroblastomas [<xref ref-type="bibr" rid="CR33">33</xref>] and embryonal rhabdomyosarcomas [<xref ref-type="bibr" rid="CR34">34</xref>]. However, these malignancies are readily distinguishable from ALCL is based on their distinct morphology. Moreover, some specific immunohistochemistry markers which were not known to be expressed in ALCL but in the other malignancies can support the diagnosis, including rhabdomyosarcoma markers MyoD1 and Myogenine and non-small cell lung cancers marker TTF-1.</p>
      <p>In general, we reported a rare case of primary intestinal ALK positive large cell lymphoma and highlighted the clinicopathological features and differential diagnosis.</p>
    </sec>
    <sec id="Sec6">
      <title>Conclusions</title>
      <p>The case reported a rare primary anaplastic large cell lymphoma in small intestine. As intestine can be involved by other types of lymphomas, the final diagnosis should be made with the combination of clinical feature, PET-CT image, pathological morphology, immunophenotype, and genetic features. For this patient, the final diagnosis was made as primary ALCL, ALK positive, stage IIIA. Although the prognosis depends on the response to chemotherapy, ALK positive may predicts a favorable prognosis in this case.</p>
    </sec>
  </body>
  <back>
    <glossary>
      <title>Abbreviations</title>
      <def-list>
        <def-item>
          <term>ALCL</term>
          <def>
            <p>Anaplastic large cell lymphoma</p>
          </def>
        </def-item>
        <def-item>
          <term>CT</term>
          <def>
            <p>Computed tomography</p>
          </def>
        </def-item>
        <def-item>
          <term>DLBCL</term>
          <def>
            <p>Diffuse large B cell lymphoma</p>
          </def>
        </def-item>
        <def-item>
          <term>EATL</term>
          <def>
            <p>Enteropathy-associated T-cell lymphoma</p>
          </def>
        </def-item>
        <def-item>
          <term>EBER</term>
          <def>
            <p>Epstein-Barr virus (EBV)-encoded small RNA</p>
          </def>
        </def-item>
        <def-item>
          <term>GI</term>
          <def>
            <p>Gastrointestinal</p>
          </def>
        </def-item>
        <def-item>
          <term>HL</term>
          <def>
            <p>Hodgkin&#x2019;s lymphoma</p>
          </def>
        </def-item>
        <def-item>
          <term>IHC</term>
          <def>
            <p>Immunohistochemistry</p>
          </def>
        </def-item>
        <def-item>
          <term>ISH</term>
          <def>
            <p>In situ hybridization</p>
          </def>
        </def-item>
        <def-item>
          <term>MALT</term>
          <def>
            <p>Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue</p>
          </def>
        </def-item>
        <def-item>
          <term>NK/TL</term>
          <def>
            <p>NK/T-cell lymphoma</p>
          </def>
        </def-item>
        <def-item>
          <term>PBL</term>
          <def>
            <p>Plasmablastic Lymphoma</p>
          </def>
        </def-item>
        <def-item>
          <term>PTCL</term>
          <def>
            <p>NOS, peripheral T-cell lymphoma, not other specified</p>
          </def>
        </def-item>
      </def-list>
    </glossary>
    <ack>
      <title>Acknowledgements</title>
      <p>Not applicable.</p>
      <sec id="FPar1">
        <title>Funding</title>
        <p>No istitutional funding, but personal of corresponding Author Tingsheng Peng.</p>
      </sec>
      <sec id="FPar2">
        <title>Availability of data and materials</title>
        <p>The data and materials are available to be shared.</p>
      </sec>
      <sec id="FPar4">
        <title>Authors&#x2019; contributions</title>
        <p>TP and QC made the final diagnosis, QC and FL drafted the manuscript and performed the literature review; TP contributed to concept, approved the final version of the manuscript. SL contributed to radiological information. NL carried out the immunohistochemical examination. LL collected the clinical data. CL participated the revision of the manuscript. All authors read and approved the final manuscript.</p>
      </sec>
      <sec id="FPar3">
        <title>Competing interests</title>
        <p>The authors declare that they have no competing interests in the manuscript.</p>
      </sec>
      <sec id="FPar5">
        <title>Consent for publication</title>
        <p>Written informed consent was obtained from the patient&#x2019;s for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.</p>
      </sec>
      <sec id="FPar6">
        <title>Ethics approval and consent to participate</title>
        <p>The authors declare that the data supporting the findings of this study are available within the article. The manuscript was approved by the Ethics Committee of The First Affiliated Hospital of Sun Yat-sen University.</p>
      </sec>
    </ack>
    <ref-list id="Bib1">
      <title>References</title>
      <ref id="CR1">
        <label>1.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Stein</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Mason</surname>
              <given-names>DY</given-names>
            </name>
            <name>
              <surname>Gerdes</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>O&#x2019;Connor</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Wainscoat</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Pallesen</surname>
              <given-names>G</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>The expression of the Hodgkin&#x2019;s disease associated antigen Ki-1 in reactive and neoplastic lymphoid tissue: evidence that Reed-Sternberg cells and histiocytic malignancies are derived from activated lymphoid cells</article-title>
          <source>Blood</source>
          <year>1985</year>
          <volume>66</volume>
          <issue>4</issue>
          <fpage>848</fpage>
          <lpage>858</lpage>
          <pub-id pub-id-type="pmid">3876124</pub-id>
        </element-citation>
      </ref>
      <ref id="CR2">
        <label>2.</label>
        <mixed-citation publication-type="other">Swerdllow SH, Campo E, Harris NL. WHO classification of tumours of haematopoietic and lymphoid tissues. 4<sup>th</sup> ed. IARC: Lyon,2008.</mixed-citation>
      </ref>
      <ref id="CR3">
        <label>3.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Stein</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Foss</surname>
              <given-names>HD</given-names>
            </name>
            <name>
              <surname>Durkop</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Marafioti</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Delsol</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Pulford</surname>
              <given-names>K</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>CD30(+) anaplastic large cell lymphoma: a review of its histopathologic, genetic, and clinical features</article-title>
          <source>Blood</source>
          <year>2000</year>
          <volume>96</volume>
          <fpage>3681</fpage>
          <lpage>3695</lpage>
          <pub-id pub-id-type="pmid">11090048</pub-id>
        </element-citation>
      </ref>
      <ref id="CR4">
        <label>4.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Carey</surname>
              <given-names>MJ</given-names>
            </name>
            <name>
              <surname>Medeiros</surname>
              <given-names>LJ</given-names>
            </name>
            <name>
              <surname>Roepke</surname>
              <given-names>JE</given-names>
            </name>
            <name>
              <surname>Kjeldsberg</surname>
              <given-names>CR</given-names>
            </name>
            <name>
              <surname>Elenitoba-Johnson</surname>
              <given-names>KS</given-names>
            </name>
          </person-group>
          <article-title>Primary anaplastic large cell lymphoma of the small intestine</article-title>
          <source>Am J Clin Pathol</source>
          <year>1999</year>
          <volume>112</volume>
          <fpage>696</fpage>
          <lpage>701</lpage>
          <pub-id pub-id-type="doi">10.1093/ajcp/112.5.696</pub-id>
          <pub-id pub-id-type="pmid">10549257</pub-id>
        </element-citation>
      </ref>
      <ref id="CR5">
        <label>5.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kim</surname>
              <given-names>DH</given-names>
            </name>
            <name>
              <surname>Lee</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Kim</surname>
              <given-names>JW</given-names>
            </name>
            <name>
              <surname>Huh</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Park</surname>
              <given-names>SH</given-names>
            </name>
            <name>
              <surname>Ha</surname>
              <given-names>HK</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Endoscopic and clinical analysis of primary T-cell lymphoma of the gastrointestinal tract according to pathological subtype</article-title>
          <source>J Gastroen Hepatol</source>
          <year>2014</year>
          <volume>29</volume>
          <fpage>934</fpage>
          <lpage>943</lpage>
          <pub-id pub-id-type="doi">10.1111/jgh.12471</pub-id>
        </element-citation>
      </ref>
      <ref id="CR6">
        <label>6.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kohno</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Ohshima</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Yoneda</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Kodama</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Shirakusa</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Kikuchi</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Clinicopathological analysis of 143 primary malignant lymphomas in the small and large intestines based on the new WHO classification</article-title>
          <source>Histopathology</source>
          <year>2003</year>
          <volume>43</volume>
          <fpage>135</fpage>
          <lpage>143</lpage>
          <pub-id pub-id-type="doi">10.1046/j.1365-2559.2003.01659.x</pub-id>
          <pub-id pub-id-type="pmid">12877728</pub-id>
        </element-citation>
      </ref>
      <ref id="CR7">
        <label>7.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Shirsat</surname>
              <given-names>HS</given-names>
            </name>
            <name>
              <surname>Vaiphei</surname>
              <given-names>K</given-names>
            </name>
          </person-group>
          <article-title>Primary gastrointestinal lymphomas&#x2014;A study of 81 Cases from a Tertiary Healthcare Centre</article-title>
          <source>Indian J Cancer</source>
          <year>2014</year>
          <volume>51</volume>
          <fpage>290</fpage>
          <lpage>292</lpage>
          <pub-id pub-id-type="doi">10.4103/0019-509X.146777</pub-id>
          <pub-id pub-id-type="pmid">25494124</pub-id>
        </element-citation>
      </ref>
      <ref id="CR8">
        <label>8.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Gurney</surname>
              <given-names>KA</given-names>
            </name>
            <name>
              <surname>Cartwright</surname>
              <given-names>RA</given-names>
            </name>
          </person-group>
          <article-title>Increasing incidence and descriptive epidemiology of extranodal non-Hodgkin lymphoma in parts of England and Wales</article-title>
          <source>Hematol J</source>
          <year>2002</year>
          <volume>3</volume>
          <fpage>95</fpage>
          <lpage>104</lpage>
          <pub-id pub-id-type="doi">10.1038/sj.thj.6200154</pub-id>
          <pub-id pub-id-type="pmid">12032871</pub-id>
        </element-citation>
      </ref>
      <ref id="CR9">
        <label>9.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Dawson</surname>
              <given-names>IM</given-names>
            </name>
            <name>
              <surname>Cornes</surname>
              <given-names>JS</given-names>
            </name>
            <name>
              <surname>Morson</surname>
              <given-names>BC</given-names>
            </name>
          </person-group>
          <article-title>Primary malignant lymphoid tumours of the intestinal tract. Report of 37 cases with a study of factors influencing prognosis</article-title>
          <source>Br J Surg</source>
          <year>1961</year>
          <volume>49</volume>
          <fpage>80</fpage>
          <lpage>89</lpage>
          <pub-id pub-id-type="doi">10.1002/bjs.18004921319</pub-id>
          <pub-id pub-id-type="pmid">13884035</pub-id>
        </element-citation>
      </ref>
      <ref id="CR10">
        <label>10.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Wang</surname>
              <given-names>GB</given-names>
            </name>
            <name>
              <surname>Xu</surname>
              <given-names>GL</given-names>
            </name>
            <name>
              <surname>Luo</surname>
              <given-names>GY</given-names>
            </name>
            <name>
              <surname>Shan</surname>
              <given-names>HB</given-names>
            </name>
            <name>
              <surname>Li</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Gao</surname>
              <given-names>XY</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Primary intestinal non-Hodgkin&#x2019;s lymphoma: a clinicopathologic analysis of 81 patients</article-title>
          <source>World J Gastroenterol</source>
          <year>2011</year>
          <volume>17</volume>
          <fpage>4625</fpage>
          <lpage>4631</lpage>
          <pub-id pub-id-type="doi">10.3748/wjg.v17.i41.4625</pub-id>
          <pub-id pub-id-type="pmid">22147970</pub-id>
        </element-citation>
      </ref>
      <ref id="CR11">
        <label>11.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Howell</surname>
              <given-names>JM</given-names>
            </name>
            <name>
              <surname>Auer-Grzesiak</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Zhang</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Andrews</surname>
              <given-names>CN</given-names>
            </name>
            <name>
              <surname>Stewart</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Urbanski</surname>
              <given-names>SJ</given-names>
            </name>
          </person-group>
          <article-title>Increasing incidence rates, distribution and histological characteristics of primary gastrointestinal non-Hodgkin lymphoma in a North American population</article-title>
          <source>Can J Gastroenterol</source>
          <year>2012</year>
          <volume>26</volume>
          <fpage>452</fpage>
          <lpage>456</lpage>
          <pub-id pub-id-type="doi">10.1155/2012/480160</pub-id>
          <pub-id pub-id-type="pmid">22803021</pub-id>
        </element-citation>
      </ref>
      <ref id="CR12">
        <label>12.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kim</surname>
              <given-names>SJ</given-names>
            </name>
            <name>
              <surname>Choi</surname>
              <given-names>CW</given-names>
            </name>
            <name>
              <surname>Mun</surname>
              <given-names>YC</given-names>
            </name>
            <name>
              <surname>Oh</surname>
              <given-names>SY</given-names>
            </name>
            <name>
              <surname>Kang</surname>
              <given-names>HJ</given-names>
            </name>
            <name>
              <surname>Lee</surname>
              <given-names>SI</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Multicenter retrospective analysis of 581 patients with primary intestinal non-hodgkin lymphoma from the Consortium for Improving Survival of Lymphoma (CISL)</article-title>
          <source>BMC Cancer</source>
          <year>2011</year>
          <volume>11</volume>
          <fpage>321</fpage>
          <pub-id pub-id-type="doi">10.1186/1471-2407-11-321</pub-id>
          <pub-id pub-id-type="pmid">21798075</pub-id>
        </element-citation>
      </ref>
      <ref id="CR13">
        <label>13.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Foukas</surname>
              <given-names>PG</given-names>
            </name>
            <name>
              <surname>de Leval</surname>
              <given-names>L</given-names>
            </name>
          </person-group>
          <article-title>Recent advances in intestinal lymphomas</article-title>
          <source>Histopathology</source>
          <year>2015</year>
          <volume>66</volume>
          <fpage>112</fpage>
          <lpage>136</lpage>
          <pub-id pub-id-type="doi">10.1111/his.12596</pub-id>
          <pub-id pub-id-type="pmid">25639480</pub-id>
        </element-citation>
      </ref>
      <ref id="CR14">
        <label>14.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Zeng</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Feldman</surname>
              <given-names>AL</given-names>
            </name>
          </person-group>
          <article-title>Genetics of anaplastic large cell lymphoma</article-title>
          <source>Leuk Lymphoma</source>
          <year>2016</year>
          <volume>57</volume>
          <fpage>21</fpage>
          <lpage>27</lpage>
          <pub-id pub-id-type="doi">10.3109/10428194.2015.1064530</pub-id>
          <pub-id pub-id-type="pmid">26104084</pub-id>
        </element-citation>
      </ref>
      <ref id="CR15">
        <label>15.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Pulford</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Lamant</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Espinos</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Jiang</surname>
              <given-names>Q</given-names>
            </name>
            <name>
              <surname>Xue</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Turturro</surname>
              <given-names>F</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>The emerging normal and disease-related roles of anaplastic lymphoma kinase</article-title>
          <source>Cell Mol Life Sci</source>
          <year>2004</year>
          <volume>61</volume>
          <fpage>2939</fpage>
          <lpage>2953</lpage>
          <pub-id pub-id-type="doi">10.1007/s00018-004-4275-9</pub-id>
          <pub-id pub-id-type="pmid">15583856</pub-id>
        </element-citation>
      </ref>
      <ref id="CR16">
        <label>16.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Xing</surname>
              <given-names>X</given-names>
            </name>
            <name>
              <surname>Feldman</surname>
              <given-names>AL</given-names>
            </name>
          </person-group>
          <article-title>Anaplastic large cell lymphomas: ALK positive, ALK negative, and primary cutaneous</article-title>
          <source>Adv Anatpathol</source>
          <year>2015</year>
          <volume>22</volume>
          <fpage>29</fpage>
          <lpage>49</lpage>
        </element-citation>
      </ref>
      <ref id="CR17">
        <label>17.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Gascoyne</surname>
              <given-names>RD</given-names>
            </name>
            <name>
              <surname>Aoun</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Wu</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Chhanabhai</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Skinnider</surname>
              <given-names>BF</given-names>
            </name>
            <name>
              <surname>Greiner</surname>
              <given-names>TC</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Prognostic significance of anaplastic lymphoma kinase (ALK) protein expression in adults with anaplastic large cell lymphoma</article-title>
          <source>Blood</source>
          <year>1999</year>
          <volume>93</volume>
          <fpage>3913</fpage>
          <lpage>3921</lpage>
          <pub-id pub-id-type="pmid">10339500</pub-id>
        </element-citation>
      </ref>
      <ref id="CR18">
        <label>18.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Savage</surname>
              <given-names>KJ</given-names>
            </name>
            <name>
              <surname>Harris</surname>
              <given-names>NL</given-names>
            </name>
            <name>
              <surname>Vose</surname>
              <given-names>JM</given-names>
            </name>
            <name>
              <surname>Ullrich</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Jaffe</surname>
              <given-names>ES</given-names>
            </name>
            <name>
              <surname>Connors</surname>
              <given-names>JM</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>ALK- anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project</article-title>
          <source>Blood</source>
          <year>2008</year>
          <volume>111</volume>
          <fpage>5496</fpage>
          <lpage>5504</lpage>
          <pub-id pub-id-type="doi">10.1182/blood-2008-01-134270</pub-id>
          <pub-id pub-id-type="pmid">18385450</pub-id>
        </element-citation>
      </ref>
      <ref id="CR19">
        <label>19.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Delsol</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Lamant</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Mariame</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Pulford</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Dastugue</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Brousset</surname>
              <given-names>P</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>A new subtype of large B-cell lymphoma expressing the ALK kinase and lacking the 2; 5 translocation</article-title>
          <source>Blood</source>
          <year>1997</year>
          <volume>89</volume>
          <fpage>1483</fpage>
          <lpage>1490</lpage>
          <pub-id pub-id-type="pmid">9057627</pub-id>
        </element-citation>
      </ref>
      <ref id="CR20">
        <label>20.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lee</surname>
              <given-names>HW</given-names>
            </name>
            <name>
              <surname>Kim</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Kim</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Ko</surname>
              <given-names>YH</given-names>
            </name>
          </person-group>
          <article-title>ALK-positive diffuse large B-cell lymphoma: report of three cases</article-title>
          <source>Hematol Oncol</source>
          <year>2008</year>
          <volume>26</volume>
          <fpage>108</fpage>
          <lpage>113</lpage>
          <pub-id pub-id-type="doi">10.1002/hon.841</pub-id>
          <pub-id pub-id-type="pmid">18220322</pub-id>
        </element-citation>
      </ref>
      <ref id="CR21">
        <label>21.</label>
        <mixed-citation publication-type="other">Elyamany G, Al ME, Alzahrani AM. Plasmablastic Lymphoma: A Review of Current Knowledge and Future Directions. Adv Hematol.2015; 2015:315289.</mixed-citation>
      </ref>
      <ref id="CR22">
        <label>22.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Iqbal</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Wright</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Rosenwald</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Gascoyne</surname>
              <given-names>RD</given-names>
            </name>
            <name>
              <surname>Weisenburger</surname>
              <given-names>DD</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Gene expression signatures delineate biological and prognostic subgroups in peripheral T-cell lymphoma</article-title>
          <source>Blood</source>
          <year>2014</year>
          <volume>123</volume>
          <fpage>2915</fpage>
          <lpage>2923</lpage>
          <pub-id pub-id-type="doi">10.1182/blood-2013-11-536359</pub-id>
          <pub-id pub-id-type="pmid">24632715</pub-id>
        </element-citation>
      </ref>
      <ref id="CR23">
        <label>23.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ferreri</surname>
              <given-names>AJM</given-names>
            </name>
            <name>
              <surname>Govi</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Pileri</surname>
              <given-names>SA</given-names>
            </name>
            <name>
              <surname>Savage</surname>
              <given-names>KJ</given-names>
            </name>
          </person-group>
          <article-title>Anaplastic large cell lymphoma, ALK-negative</article-title>
          <source>Crit Rev Oncol Hematol</source>
          <year>2013</year>
          <volume>85</volume>
          <fpage>206</fpage>
          <lpage>215</lpage>
          <pub-id pub-id-type="doi">10.1016/j.critrevonc.2012.06.004</pub-id>
          <pub-id pub-id-type="pmid">22789917</pub-id>
        </element-citation>
      </ref>
      <ref id="CR24">
        <label>24.</label>
        <mixed-citation publication-type="other">Krenacs L,&#xA0;Wellmann A,&#xA0;Sorbara L,&#xA0;Himmelmann AW,&#xA0;Bagdi E,&#xA0;Jaffe ES,&#xA0;et al. Cytotoxic&#xA0;cell&#xA0;antigen expression in&#xA0;anaplastic&#xA0;large&#xA0;cell&#xA0;lymphomas of T- and null-cell&#xA0;type and Hodgkin's disease: evidence for distinct cellular origin. Blood.&#xA0;1997;89(3):980-9.</mixed-citation>
      </ref>
      <ref id="CR25">
        <label>25.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Jaffe</surname>
              <given-names>ES</given-names>
            </name>
            <name>
              <surname>Nicolae</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Pittaluga</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>Peripheral T-cell and NK-cell lymphomas in the WHO classification: pearls and pitfalls</article-title>
          <source>Mod Pathol</source>
          <year>2013</year>
          <volume>26</volume>
          <issue>Suppl 1</issue>
          <fpage>S71</fpage>
          <lpage>S87</lpage>
          <pub-id pub-id-type="doi">10.1038/modpathol.2012.181</pub-id>
          <pub-id pub-id-type="pmid">23281437</pub-id>
        </element-citation>
      </ref>
      <ref id="CR26">
        <label>26.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Barry</surname>
              <given-names>TS</given-names>
            </name>
            <name>
              <surname>Jaffe</surname>
              <given-names>ES</given-names>
            </name>
            <name>
              <surname>Sorbara</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Raffeld</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Pittaluga</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>Peripheral T-cell lymphomas expressing CD30 and CD15</article-title>
          <source>Am J Surg Pathol</source>
          <year>2003</year>
          <volume>27</volume>
          <fpage>1513</fpage>
          <lpage>1522</lpage>
          <pub-id pub-id-type="doi">10.1097/00000478-200312000-00003</pub-id>
          <pub-id pub-id-type="pmid">14657710</pub-id>
        </element-citation>
      </ref>
      <ref id="CR27">
        <label>27.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sieniawski</surname>
              <given-names>MK</given-names>
            </name>
            <name>
              <surname>Lennard</surname>
              <given-names>AL</given-names>
            </name>
          </person-group>
          <article-title>Enteropathy-associated T-cell lymphoma: epidemiology, clinical features, and current treatment strategies</article-title>
          <source>Curr Hematol Malig Rep</source>
          <year>2011</year>
          <volume>6</volume>
          <fpage>231</fpage>
          <lpage>240</lpage>
          <pub-id pub-id-type="doi">10.1007/s11899-011-0097-7</pub-id>
          <pub-id pub-id-type="pmid">21912848</pub-id>
        </element-citation>
      </ref>
      <ref id="CR28">
        <label>28.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Jiao</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Zheng</surname>
              <given-names>Z</given-names>
            </name>
            <name>
              <surname>Jiang</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Zhang</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>B</given-names>
            </name>
          </person-group>
          <article-title>Enteropathy-associated T-cell lymphoma presenting with gastrointestinal tract symptoms: A report of two cases and review of diagnostic challenges and clinicopathological correlation</article-title>
          <source>Oncol Lett</source>
          <year>2014</year>
          <volume>8</volume>
          <fpage>91</fpage>
          <lpage>94</lpage>
          <pub-id pub-id-type="pmid">24959225</pub-id>
        </element-citation>
      </ref>
      <ref id="CR29">
        <label>29.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ferreri</surname>
              <given-names>AJ</given-names>
            </name>
            <name>
              <surname>Govi</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Pileri</surname>
              <given-names>SA</given-names>
            </name>
            <name>
              <surname>Savage</surname>
              <given-names>KJ</given-names>
            </name>
          </person-group>
          <article-title>Anaplastic large cell lymphoma</article-title>
          <source>ALK-negative. Crit Rev Oncol Hematol.</source>
          <year>2013</year>
          <volume>85</volume>
          <issue>2</issue>
          <fpage>206</fpage>
          <lpage>15</lpage>
          <pub-id pub-id-type="doi">10.1016/j.critrevonc.2012.06.004</pub-id>
          <pub-id pub-id-type="pmid">22789917</pub-id>
        </element-citation>
      </ref>
      <ref id="CR30">
        <label>30.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Fu</surname>
              <given-names>X</given-names>
            </name>
            <name>
              <surname>Jiang</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Tian</surname>
              <given-names>XY</given-names>
            </name>
            <name>
              <surname>Li</surname>
              <given-names>Z</given-names>
            </name>
          </person-group>
          <article-title>Pulmonary epithelioid inflammatory myofibroblastic sarcoma with multiple bone metastases: case report and review of literature</article-title>
          <source>Diagn Pathol</source>
          <year>2015</year>
          <volume>10</volume>
          <fpage>106</fpage>
          <pub-id pub-id-type="doi">10.1186/s13000-015-0358-1</pub-id>
          <pub-id pub-id-type="pmid">26178751</pub-id>
        </element-citation>
      </ref>
      <ref id="CR31">
        <label>31.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Parra-Herran</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Quick</surname>
              <given-names>CM</given-names>
            </name>
            <name>
              <surname>Howitt</surname>
              <given-names>BE</given-names>
            </name>
            <name>
              <surname>Dal Cin</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Quade</surname>
              <given-names>BJ</given-names>
            </name>
            <name>
              <surname>Nucci</surname>
              <given-names>MR</given-names>
            </name>
          </person-group>
          <article-title>Inflammatory myofibroblastic tumor of the uterus: clinical and pathologic review of 10 cases including a subset with aggressive clinical course</article-title>
          <source>Am J Surg Pathol</source>
          <year>2015</year>
          <volume>39</volume>
          <fpage>157</fpage>
          <lpage>168</lpage>
          <pub-id pub-id-type="doi">10.1097/PAS.0000000000000330</pub-id>
          <pub-id pub-id-type="pmid">25321329</pub-id>
        </element-citation>
      </ref>
      <ref id="CR32">
        <label>32.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Mano</surname>
              <given-names>H</given-names>
            </name>
          </person-group>
          <article-title>Non-solid oncogenes in solid tumors: EML4-ALK fusion genes in lung cancer</article-title>
          <source>Cancer Sci</source>
          <year>2008</year>
          <volume>99</volume>
          <fpage>2349</fpage>
          <lpage>2355</lpage>
          <pub-id pub-id-type="doi">10.1111/j.1349-7006.2008.00972.x</pub-id>
          <pub-id pub-id-type="pmid">19032370</pub-id>
        </element-citation>
      </ref>
      <ref id="CR33">
        <label>33.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sridhar</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Al-Moallem</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Kamal</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Terrile</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Stallings</surname>
              <given-names>RL</given-names>
            </name>
          </person-group>
          <article-title>New insights into the genetics of neuroblastoma</article-title>
          <source>Mol Diagn Ther</source>
          <year>2013</year>
          <volume>17</volume>
          <fpage>63</fpage>
          <lpage>69</lpage>
          <pub-id pub-id-type="doi">10.1007/s40291-013-0019-6</pub-id>
          <pub-id pub-id-type="pmid">23329364</pub-id>
        </element-citation>
      </ref>
      <ref id="CR34">
        <label>34.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Yoshida</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Shibata</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Wakai</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Ushiku</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Tsuta</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Fukayama</surname>
              <given-names>M</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Anaplastic lymphoma kinase status in rhabdomyosarcomas</article-title>
          <source>Mod Pathol</source>
          <year>2013</year>
          <volume>26</volume>
          <fpage>772</fpage>
          <lpage>781</lpage>
          <pub-id pub-id-type="doi">10.1038/modpathol.2012.222</pub-id>
          <pub-id pub-id-type="pmid">23307059</pub-id>
        </element-citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>
